Literature DB >> 2903400

Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy.

U Hedner, S Glazer, K Pingel, K A Alberts, M Blombäck, S Schulman, H Johnsson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2903400     DOI： 10.1016/s0140-6736(88)90259-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  22 in total

Review 1.  Tissue factor controversies.

Authors:  Kenneth G Mann; Jolanta Krudysz-Amblo; Saulius Butenas
Journal:  Thromb Res       Date:  2012-03-07       Impact factor: 3.944

Review 2.  The use of recombinant activated coagulation factor VII for spine surgery.

Authors:  Richard B Weiskopf
Journal:  Eur Spine J       Date:  2004-05-25       Impact factor: 3.134

Review 3.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

4.  Poly-N-acetylglucosamine fibers amplify the effectiveness of recombinant factor VIIA on clot formation in hemophilia B canine blood.

Authors:  Thomas H Fischer; Timothy C Nichols; Christopher M Scull; Carr J Smith; Marina Demcheva
Journal:  J Trauma       Date:  2011-08

5.  Correction of knee flexion contracture at the time of surgical fixation of a femoral supracondylar fracture in a haemophiliac with inhibitors.

Authors:  Laura Candiotto; Franco W Fullone; Alberto Ricciardi; Paolo Radossi; Giuseppe Tagariello
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

6.  Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.

Authors:  Marcus E Carr; Thomas P Loughran; John A Cardea; Wade K Smith; Jan G Kuhn; Maribeth V Dottore
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

Review 7.  Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date.

Authors:  Muriel Giansily-Blaizot; Jean-François Schved
Journal:  Ther Adv Hematol       Date:  2017-11-03

Review 8.  The emerging role of recombinant-activated factor VII in neurocritical care.

Authors:  Matthew E Fewel; Paul Park
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 9.  Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients.

Authors:  John Puetz
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

Review 10.  The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.

Authors:  Rivka Yatuv; Micah Robinson; Inbal Dayan-Tarshish; Moshe Baru
Journal:  Int J Nanomedicine       Date:  2010-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.